Ekso Bionics Approves Reverse Stock Split Plan

An announcement from EKSO BIONICS ( (EKSO) ) is now available.

On May 16, 2025, Ekso Bionics held its Annual Meeting of Stockholders where several key proposals were approved, including a reverse stock split at a ratio of 1-for-15, effective May 27, 2025. This move is primarily intended to increase the per-share trading price and help the company regain compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Spark’s Take on EKSO Stock

According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral.

EKSO BIONICS’ overall score reflects significant financial challenges, particularly in achieving profitability and positive cash flow. Despite some improvements in operational efficiency and strategic partnerships, these are overshadowed by declining revenue and economic uncertainties impacting its enterprise segment. Technical indicators suggest bearish momentum, and the stock’s valuation remains unattractive due to its negative P/E ratio.

To see Spark’s full report on EKSO stock, click here.

More about EKSO BIONICS

Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications. The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol ‘EKSO’.

Average Trading Volume: 1,996,424

Technical Sentiment Signal: Sell

Current Market Cap: $9.61M

For detailed information about EKSO stock, go to TipRanks’ Stock Analysis page.